Sangamo Therapeutics Inc
![Sangamo Therapeutics Inc](https://api.admiralmarkets.com/trade_icons/bright-128/SGMO.png)
Closed
Sector Healthcare
0.72 -2.7
Overview
Share price change
24h
Min
0.71
Max
0.73
Sales | -7.4M 2M |
---|---|
EPS | -0.34 |
Employees | 405 |
Recommendations | Buy |
---|---|
12 Months Forecast | +281.94 upside |
Next Earnings | 30 Oct 2024 |
---|
Market Cap | -2.3M 114M |
---|---|
Previous open | 3.42 |
Previous close | 0.72 |
News Sentiment
By Acuity
50%
50%
321 / 365 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Sangamo Therapeutics Inc Chart
Related News
Peer Comparison
Price change
Sangamo Therapeutics Inc Forecast
Price Target
By TipRanks
281.94% upside
12 Months Forecast
Average 2.75 USD 281.94%
High 5 USD
Low 1 USD
Based on 6 Wall Street analysts offering 12 month price targets forSangamo Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
321 / 365 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
EBITDA
Operating profit
$
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.